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2Worldwide efforts are being made to end tuberculosis (TB) by 2035, following the ambitions outlined 
in the World Health Organization’s  End TB strategy [1] and the United Nations Sustainable 
Development Goals [2]. Countries with a low incidence of TB, i.e. less than 10 incident cases per 100 
000 population per year, should strive for TB elimination [3]. To this end, timely detection and treatment 
of latent tuberculosis infection (LTBI) is an important intervention [3]. Currently, the existence and 
implementation of national strategies including public health interventions targeting LTBI is 
heterogeneous across the European Union/European Economic Area (EU/EEA) [4]. To support the 
EU/EEA countries with developing national policies, as well as the planning and implementation of 
programmatic management of LTBI into national strategies for TB control, the European Centre for 
Disease Prevention and Control (ECDC) conducted a comprehensive assessment of the available 
evidence and developed an evidence-based guidance [5]. The guidance, published in October 2018, 
elaborates on population-level measures for LTBI management tailored to the EU/EAA context and it 
is complementary to the World Health Organization (WHO) guidelines [6]. Here we summarize the 
process that was followed to develop the guidance and we outline the key components proposed for 
programmatic management of LTBI, to inform European healthcare professionals. 
The ECDC guidance includes four key areas: target risk groups for programmatic management of LTBI; 
diagnosis of LTBI; treatment of LTBI; and programmatic issues of LTBI management. The key areas 
and corresponding research questions were identified through consultation with experts [7]. Scientific 
evidence was collected through systematic literature reviews, with additional evidence derived from 
mathematical modelling and cost-effectiveness analyses [8-10], and the evidence was reviewed and 
appraised by an ad hoc scientific panel.
The systematic literature reviews collected available scientific evidence on target groups, diagnosis and 
treatment of LTBI, and programmatic issues and were performed in collaboration with WHO [11,12]. 
Additional steps for identification, collection and appraisal of relevant peer-reviewed and grey literature 
were conducted, as described in a detailed technical report [8]. The evidence showed an increased risk 
of becoming latently infected and/or progressing to active TB disease for people living with HIV, 
immunocompromised patients, close contacts of TB patients (risk of progression especially high in 
children), migrants, healthcare workers, prisoners and homeless people [11,12]. Both the tuberculin 
skin test (TST) and the interferon gamma release assays (IGRA) were regarded as suitable and cost-
effective diagnostic tools [8,11,12]. Similarly, various treatment regimens showed good efficacy and 
cost-effectiveness. Short treatment regimens (i.e. less than 6-month treatment duration) had better 
adherence and completion rates [8,13]. Several interventions were shown to improve initiation, 
adherence and completion of LTBI treatment, including provision of monetary incentives to people who 
inject drugs; nurse-led community-based case management in homeless people, educational sessions 
with prison inmates and counsellor or peer-based social support [8,14,15].
The deterministic mathematical model for TB transmission estimated the contribution of LTBI 
screening and treatment strategies on reducing TB transmission. Various at-risk populations were 
considered in the model, i.e. people who inject drugs, homeless people, prisoners and migrants from 
high TB incidence countries. The model was applied to data from four EU countries: the Netherlands, 
the Czech Republic, Portugal, and Spain.  Modelling results suggested that screening for and treatment 
of LTBI in prisoners or migrants from high-endemic countries at entry in the country, people who inject 
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3drugs and homeless people all result in a decrease in pulmonary TB incidence. The order of importance 
of each of these groups depends on the country. The mathematical model informed the assessment of 
cost-effectiveness of selected LTBI screening and treatment strategies. Across all at-risk populations 
considered, model results found that performing a TST and if positive an IGRA was the most cost-
effective strategy for diagnosing LTBI. The cost-effectiveness analysis further suggested that LTBI 
screening for migrants at entry, LTBI screening for prisoners and LTBI screening for people who inject 
drugs/homeless people would all be cost-effective. The cost-effectiveness of screening and treatment 
of four other groups was also assessed using cohort model variants: travellers, healthcare workers, 
immunocompromised patients, and TB contacts. LTBI screening and treatment of travellers and 
healthcare workers would only be cost-effective under unrealistically high levels of increased risk for 
transmission in these populations. For immunocompromised patients LTBI screening and treatment 
would be cost-effective if they are part of a migrant population or native populations in European 
countries with a relatively high TB burden (i.e. more than 50 incident cases per 100 000 population). 
For close contacts of active pulmonary TB patients the modelling found LTBI screening to be cost-
effective [9,10], which is in line with existing field studies [16,17].
 
Based on the assessment of the scientific evidence and the expert opinion of the ad hoc scientific panel, 
ECDC identified key components for implementation of programmatic management of LTBI (Table 
1). Target groups proposed to be prioritised for LTBI screening and treatment are: people living with 
HIV; immunocompromised persons (patients on anti-TNF alpha treatment, patients preparing for 
transplantation, patients with end-stage renal diseases and/or preparing for dialysis); patients with 
silicosis; people with pulmonary fibrotic lesions; and contacts of infectious TB cases. Additional at-risk 
groups may be considered depending on the TB epidemiology. For diagnosing LTBI, both TST and 
IGRA or a combination can be used. Table 2 summarises practical considerations for the selection of 
testing methods, based on the expert opinion of the ad hoc scientific panel.  For successful 
implementation, LTBI screening should be conceptualised as a comprehensive strategy that requires 
availability of and accessibility to diagnostic tests, and also the intention to provide LTBI treatment (if 
appropriate) and the implementation of interventions promoting the uptake and completion of LTBI 
screening procedures. For treatment of LTBI the following regimens can be considered: isoniazid alone 
(for 6–9 months), rifampicin alone (for 3–4 months), isoniazid and rifapentine (once weekly for 12 
weeks) and isoniazid and rifampicin (for 3–4 months) [13]. The selection of the most appropriate LTBI 
treatment regimen should be based on an individual risk assessment [18,19]. Patient-centred case 
management including provision of material incentives and enablers, counselling and education, peer-
based support and culturally-sensible approaches can be considered as part of an integrated 
programmatic strategy for LTBI management.
Country-level implementation of the suggested public health measures will need to take into account 
the TB epidemiology in various risk groups, health system structure, resource allocation and political 
commitment. In-depth knowledge of the local epidemiological profile will facilitate the identification 
of at-risk groups to be prioritised for LTBI screening and treatment. Also, provision of high-quality 
programmatic management of LTBI will benefit from a well-coordinated collaboration between 
different levels of the health system (i.e. local, regional and national) and linkages with other health 
programmes (e.g. HIV clinics). The healthcare work force will need to be made aware with appropriate 
training as necessary, on new/updated national guidelines, procedures and specific technical (i.e. 
administration and interpretation of diagnostic tests) and social (i.e. establishing rapport and providing 
psycho-social support) skills.
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4We acknowledge that physicians will be confronted with the challenge of assessing the patient-level 
risk and benefits while implementing these population-level public health activities [20,21]. 
Educational interventions and incentives for frontline health care workers may support them in making 
these assessments and help overcome provider-related barriers to access LTBI diagnosis and treatment 
[22]. We also acknowledge the necessity to understand health practitioners’ perceptions of and attitudes 
towards LTBI management to tailor information and advice that aims to increase their adherence to 
national guidelines. 
Similarly, patient-related barriers such as poor health literacy and barriers related to cultural background 
and/or language, should be minimised [23,24]. Efforts can include implementation of patient-centred 
approaches that take into consideration the social context and provision of psychological, social and 
financial support to at-risk populations [25].
Monitoring and evaluation of the programmatic approach to LTBI management can pose a major 
challenge for a national TB control programme, but is important to tackle. We encourage EU/EEA 
Member States to create or continue improving their LTBI surveillance systems, striving for data 
completeness and more accurate reporting of those eligible, tested and treated for LTBI. These efforts 
will contribute to quantify the country-specific cascade of care for LTBI and help identify areas for 
adaptation and improvement of LTBI programmatic management [26].  
Finally, implementation and scale up of programmatic management of LTBI would benefit from the 
exchange of lessons learned and experiences gained. There are already some published examples from 
European settings that show the importance of documenting local or national experiences [27-29]. 
Operational research on the effectiveness and cost-effectiveness of implemented LTBI interventions 
could help us further our understanding of the actual impact of programmatic LTBI management.
Page 6 of 9European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5Table 1. Summary of the European Centre for Disease Prevention and Control guidance on 
programmatic management of Latent Tuberculosis Infection in the European Union and European 
Economic Area [5]
Key components Public health measures
Target groups 
Identification of groups at-risk of 
having LTBI and/or an increased 
risk of progressing to active TB
Prioritization of target groups for LTBI screening:
− people living with HIV; 
− immunocompromised persons, (patients on anti-TNF alpha 
treatment, patients preparing for transplantation, patients with 
end-stage renal diseases and/or preparing for dialysis);
− patients with silicosis;
− people with pulmonary fibrotic lesions;
− contacts of infectious  TB cases.
Diagnosis of LTBI 
Definition of diagnostic approach 
for LTBI detection, including both 
the selection of diagnostic test(s) 
and the diagnostic algorithm most 
appropriate for each target group
Implementation of comprehensive strategy including :
− use of tuberculin skin test and interferon gamma release assays 
(alone or a combination) to diagnose LTBI;
− availability of and accessibility to diagnostic tests;
− intention to provide LTBI treatment (if appropriate); 
− implementation of interventions promoting the uptake and 
completion of LTBI screening procedures. 
Treatment of LTBI 
Provision of LTBI treatment using 
treatment regimens that are 
effective and promote adherence 
and completion by different target 
groups
Selection of LTBI treatment regimen from the following treatment 
regimens based on an individual risk assessment:
− isoniazid alone (for 6–9 months),
− rifampicin alone (for 3–4 months),
− isoniazid and rifapentine (for three months)
− isoniazid and rifampicin (for 3–4 months) 
Programmatic issues
Implementation of patient-centred 
strategies for service delivery.
Implementation of an integrated strategy including:
− material incentives and enablers; 
− counselling and education; 
− peer-based support;
− culturally-sensible approaches.
Effective health education and 
communication with target groups 
and healthcare providers.
Implementation of a comprehensive educational programme aiming 
at increasing awareness of the importance of detecting and treating 
LTBI.
Programme monitoring and 
evaluation.
Implementation of programme monitoring and evaluation including:
− Establishment of a case-based registry of TB contacts identified 
during routine contact investigations.
− Revision/development of data collection processes.
− Definition of performance indicators.
− Implementation of regular programme monitoring, aligned with 
global [1] and regional [30] monitoring and evaluation 
frameworks
HIV= human immunodeficiency virus; LTBI= latent tuberculosis infection; TB=tuberculosis; TNF= tumour 
necrosis factor.
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6Table 2. Considerations for selection of latent tuberculosis infection testing method [5].
Target groups Preferred test Reason
Children under 5 years of age TST Children’s immune system, difficulty of 
drawing blood, little data on performance of 
IGRAs in young children.
Vulnerable and hard-to-reach 
populations1 
IGRA No need for a second visit to read the test 
result.
Immunocompromised patients 
(including PLHIV)
Combination of TST and 
IGRA (parallel testing)2
LTBI tests are less sensitive in 
immunocompromised people. In order not to 
miss Mycobacterium tuberculosis infected 
people who may face significant adverse 
health effects due to TB, a more inclusive 
approach is advisable. 
Migrant populations IGRA or TST 
acceptable.
(IGRA for large 
numbers)
No need for a second visit to read the IGRA 
result. 
BCG-vaccinated people IGRA TST may be affected by prior vaccination with 
BCG.
1 Adults, young people and children whose social circumstances or lifestyle, or those or their parents or carers, 
make it difficult to recognise TB symptoms, access health services, self-administer treatment and attend regular 
healthcare appointments [25].
2After the initiation of antiretroviral treatment, repeated testing for LTBI may be considered for PLHIV 
previously known to have negative TST or IGRA results [31].
BCG= Bacillus Calmette-Guerin; IGRA= interferon gamma release assay; LTBI= latent tuberculosis infection; 
PLHIV=people living with human immunodeficiency virus; TB= tuberculosis; TST= tuberculosis skin test.
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